Should all adjunctive corticosteroid therapy be avoided in the management of hemodynamically stabile Staphylococcus aureus bacteremia?

详细信息    查看全文

• 作者：E. Forsblom ; A.-M. Nurmi ; E. Ruotsalainen…
• 刊名：European Journal of Clinical Microbiology & Infectious Diseases
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：35
• 期：3
• 页码：471-479
• 全文大小：399 KB
• 参考文献：1.Rieg S, Peyerl-Hoffmann G, de With K et al (2009) Mortality of S. aureus bacteremia and infectious diseases specialist consultation–a study of 521 patients in Germany. J Infect 59(4):232–239CrossRef PubMed
  2.Pragman AA, Kuskowski MA, Abraham JM et al (2012) Infectious disease consultation for staphylococcus aureus bacteremia improves patient management and outcomes. Infect Dis Clin Pract 20(4):261–267CrossRef
  3.Forsblom E, Ruotsalainen E, Ollgren J, Järvinen A (2012) Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus bacteraemia. Clin Infect Dis 56(4):527–535CrossRef PubMed
  4.Kaech C, Elzi L, Sendi P et al (2006) Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 12(4):345–352CrossRef PubMed
  5.Hill PC, Birch M, Chambers S et al (2001) Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J 31(2):97–103CrossRef PubMed
  6.Choi SH, Cho SY, Park JH, Chung JW (2011) Impact of infectious-disease specialist consultations on outcomes of Staphylococcus aureus bacteremia in a hospital with a low volume of patients with S. aureus bacteremia. J Infect 62(2):181–185CrossRef PubMed
  7.Ammerlaan H, Seifert H, Harbarth S et al (2009) Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 49(7):997–1005CrossRef PubMed
  8.Fowler VG Jr, Olsen MK, Corey GR et al (2003) Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163(17):2066–2072CrossRef PubMed
  9.Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36(1):53–59CrossRef PubMed
  10.Snyder DS, Unanue ER (1982) Corticosteroids inhibit murine macrophage Ia expression and interleukin-1 production. J Immunol 129(5):1803–1809PubMed
  11.Parant M, Le Contel C, Parant F, Chedid L (1991) Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res 10(4):265–71PubMed
  12.Schumer W (1976) Steroids in the treatment of clinical septic shock. Ann Surg 184(3):333–341PubMedCentral CrossRef PubMed
  13.Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317(11):653–658CrossRef PubMed
  14.Sprung CL, Caralis PV, Marcial EH et al (1984) The effect of high-dose corticosteroids in patients with septic shock. N Engl J Med 311(18):1137–1143CrossRef PubMed
  15.Lefering R, Neugebauer EAM (1995) Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 23(7):1294–1303CrossRef PubMed
  16.Cronin L, Cook DJ, Carlet J et al (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23(8):1430–1439CrossRef PubMed
  17.Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26(4):645–650CrossRef PubMed
  18.Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862–871CrossRef PubMed
  19.Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y (2004) Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 329(7464):480–488PubMedCentral CrossRef PubMed
  20.Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y (2004) Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 1:CD002243PubMed
  21.Moran JL, Graham PL, Rockliff S, Bersten AD (2010) Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Crit Care 14(4):R134PubMedCentral CrossRef PubMed
  22.Forsblom E, Ruotsalainen E, Mölkänen T, Ollgren J, Lyytikäinen O, Järvinen A (2011) Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and community-associated Staphylococcus aureus bacteraemia. J Hosp Infect 78(2):102–107CrossRef PubMed
  23.Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH (2014) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1(9):CD001288
  24.van der Goes MC, Jacobs JW, Bijlsma JW (2014) The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects. Arthritis Res Ther 13(16)Suppl 2):S2CrossRef
  25.Berghauser Pont LM, Dammers R, Schouten JW, Lingsma HF, Dirven CM (2012) Clinical factors associated with outcome in chronic subdural hematoma: a retrospective cohort study of patients on preoperative corticosteroid therapy. Neurosurgery 70(4):873–880CrossRef PubMed
  26.Dran G, Berthier F, Fontaine D, Rasenrarijao D, Paquis P (2007) Effectiveness of adjuvant corticosteroid therapy for chronic subdural hematoma: a retrospective study of 198 cases. Neurochirurgie 53(6):477–482CrossRef PubMed
  27.Yiannopoulou KG, Floudas CS, Efthymiou AE, Karydakis KD (2008) Reversal of tetraparesis due to staphylococcal cervical spondylodiscitis associated with anterior epidural abscess after conservative treatment. Acta Neurochir 150(9):927–928CrossRef PubMed
  28.McKinsey DS, McMurray TI, Flynn JM (1990) Immune complex glomerulonephritis associated with Staphylococcus aureus bacteremia: response to corticosteroid therapy. Rev Infect Dis 12(1):125–127CrossRef PubMed
  29.Ruotsalainen E, Järvinen A, Koivula I et al (2006) Finlevo Study Group: Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 259(2):179–190CrossRef PubMed
  30.Forsblom E, Ruotsalainen E, Järvinen A (2015) Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus—a retrospective cohort study. PLoS One 13:10:e0122824
  31.McCabe WR, Jackson GG (1962) Gram negative bacteraemia. Etiology and ecology. Arch Intern Med 110:847–855CrossRef
  32.Levy MM, Fink MP, Marshall JC et al (2003) SCCM/ESICM/ ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med 31(4):1250–1256CrossRef PubMed
  33.Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36(11):1418–1423CrossRef PubMed
  34.Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML (1999) Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY-Participants Group. Diagn Microbiol Infect Dis 33(4):283–297CrossRef PubMed
  35.Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M (2005) The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 37(8):572–578CrossRef PubMed
  36.Kim SH, Kim KH, Hb K et al (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 52(1):192–197PubMedCentral CrossRef PubMed
  37.Conterno LO, Wey SB, Castelo A (1998) Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 19(1):32–37CrossRef PubMed
  38.Mylotte JM, Tayara A (2000) Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 31(5):1170–1174CrossRef PubMed
  39.Honda H, Krauss MJ, Jones JC et al (2010) The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 123(7):631–637PubMedCentral CrossRef PubMed
  40.Nagao M, Iinuma Y, Saito T et al (2009) Close cooperation between infectious disease physicians and attending physicians results in better outcomes for patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 16(12):1783–1788CrossRef
  
• 作者单位：E. Forsblom (1) (2)
  A.-M. Nurmi (1)
  E. Ruotsalainen (1)
  A. Järvinen (1)
  
  1. Division of Infectious Diseases, Inflammation Center, Helsinki University Central Hospital, Helsinki, Finland
  2. Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Aurora Hospital, Nordenskiöldinkatu 26, Building 3, P.O. Box 348, 00029, HUS Helsinki, Finland
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Medical Microbiology
  Internal Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1435-4373

文摘

The purpose of this study was to examine the prognostic impact of corticosteroids in hemodynamically stabile Staphylococcus aureus bacteremia (SAB). There were 361 hemodynamically stabile methicillin-sensitive SAB patients with prospective follow-up and grouping according to time-point, dose and indication for corticosteroid therapy. To enable analyses without external interfering corticosteroid therapy all patients with corticosteroid therapy equivalent to prednisone >10 mg/day for ≥1 month prior to positive blood culture results were excluded. Twenty-five percent (92) of patients received corticosteroid therapy of which 11 % (40) had therapy initiated within 1 week (early initiation) and 9 % (31) had therapy initiated 2–4 weeks after (delayed initiation) positive blood culture. Twenty-one patients (6 %) had corticosteroid initiated after 4 weeks and were not included in the analyses. A total of 55 % (51/92) received a weekly prednisone dose >100 mg. Patients with early initiated corticosteroid therapy had higher mortality compared to patients treated without corticosteroid therapy at 28 days (20 % vs. 7 %) (OR, 3.11; 95%CI, 1.27–7.65; p < 0.05) and at 90 days (30 % vs. 10 %) (OR, 4.01; 95%CI, 1.82–8.81; p < 0.001). Considering all prognostic markers, early initiated corticosteroid therapy predicted 28-day (HR, 3.75; 95%CI, 1.60–8.79; p = 0.002) and 90-day (HR, 3.10; 95%CI, 1.50–6.39; p = 0.002) mortality in Cox proportional hazards regression analysis. When including only patients receiving early initiated corticosteroid therapy with prednisone ≥100 mg/week the negative prognostic impact on 28-day mortality was accentuated (HR 4.8, p = 0.001). Corticosteroid therapy initiation after 1 week of positive blood cultures had no independent prognostic impact. Early initiation of corticosteroid therapy may be associate to increased mortality in hemodynamically stabile SAB.